Related Experiment Video

Updated: Aug 13, 2026

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms
06:50

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms

Published on: September 16, 2022

Pharmacological advances in the treatment of invasive candidiasis

Daniel H Deck1, B Joseph Guglielmo

  • 1San Francisco General Hospital, San Francisco, CA, USA. Daniel.Deck@sfdph.org

Expert Review of Anti-Infective Therapy
|January 31, 2006
PubMed

Insights

Invasive candidiasis management is improving with new antifungal drugs and susceptibility testing. These advances offer better treatment options for critically ill and immunocompromised patients.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive candidiasis is a frequent hospital-acquired infection, particularly in critically ill and immunocompromised individuals.
  • Optimizing antifungal therapy selection is crucial for improving patient outcomes.

Purpose of the Study:

  • To review recent advancements in antifungal therapy and diagnostic testing for invasive candidiasis.
  • To highlight the impact of new antifungal agents and susceptibility testing on patient management.

Main Methods:

  • Review of current literature on invasive candidiasis treatment.
  • Analysis of the clinical utility of new antifungal agents (triazoles, echinocandins).
  • Discussion on the role of antifungal susceptibility testing and diagnostic advancements.

Main Results:

  • Newer antifungal agents like fluconazole, voriconazole, and echinocandins demonstrate excellent activity against Candida species.
  • These agents are less toxic than older drugs, with triazoles offering oral administration benefits.
  • Standardized antifungal susceptibility testing is becoming more available, aiding therapy selection.

Conclusions:

  • Advances in antifungal agents and susceptibility testing are revolutionizing invasive candidiasis management.
  • Future adoption of diagnostic tests and susceptibility testing will significantly impact clinical practice.
  • Optimized antifungal selection leads to improved treatment strategies for high-risk patient populations.

More Related Videos

Curcuminoid-Mediated Antimicrobial Photodynamic Therapy on a Murine Model of Oral Candidiasis06:39

Curcuminoid-Mediated Antimicrobial Photodynamic Therapy on a Murine Model of Oral Candidiasis

Published on: October 27, 2023

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis08:48

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis

Published on: March 19, 2019

Related Concept Videos

Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...